Gavin Wood sold $950 of ADAPY
Chief Financial Officer at Adaptimmune Therapeutics PLC. 96,000 shares at an average of $0.01, traded Sep 2, 2025, filed Sep 3, 2025.
Score components
- +22RoleCFO
- 0Trade size$950 at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +190.6%, 3m -20.8%, 6m -71.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-087085, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 2, 2025 | SOpen-market sale Ordinary Shares with a nominal value of GBP0.001 per share | -96,000 | $0.01 | $950 | 0 | Sep 3, 2025 |
Related signals
Other insiders at Adaptimmune Therapeutics PLC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $2,091 207,000 shares | -17% | |
| 56Moderate | Adaptimmune Therapeutics PLC | Ali Behbahani director | $229k 19,500,000 shares | -100% | |
| 47Moderate | ADAPYsell Adaptimmune Therapeutics PLC | EcoR1 Capital, LLC owner | $6.9M 64,052,538 shares | -39% | |
| 50Moderate | Adaptimmune Therapeutics PLC | Adrian Rawcliffe Chief Executive Officer | $18k 30,601 shares | -41% | |
| 45Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $3,243 5,584 shares | -43% | |
| 40Moderate | Adaptimmune Therapeutics PLC | John Lunger Chief Patient Supply Officer | $3,243 5,584 shares | -43% | |
| 40Moderate | Adaptimmune Therapeutics PLC | Elliot Norry Chief Medical Officer | $3,243 5,584 shares | -43% | |
| 55Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $11k 19,542 shares | -193% | |
| 50Moderate | Adaptimmune Therapeutics PLC | John Lunger Chief Patient Supply Officer | $11k 19,542 shares | -193% | |
| 50Moderate | Adaptimmune Therapeutics PLC | Elliot Norry Chief Medical Officer | $13k 22,195 shares | -219% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.